Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
KNSA 
Kiniksa Pharmaceuticals Ltd (KNSA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/17/2025: KNSA (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $46.5
1 Year Target Price $46.5
| 4 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -29.58% | Avg. Invested days 30 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/17/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.65B USD | Price to earnings Ratio 715.4 | 1Y Target Price 46.5 |
Price to earnings Ratio 715.4 | 1Y Target Price 46.5 | ||
Volume (30-day avg) 6 | Beta 0.2 | 52 Weeks Range 17.82 - 37.34 | Updated Date 09/16/2025 |
52 Weeks Range 17.82 - 37.34 | Updated Date 09/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.05 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 0.9% | Operating Margin (TTM) 12.86% |
Management Effectiveness
Return on Assets (TTM) 0.47% | Return on Equity (TTM) 1.03% |
Valuation
Trailing PE 715.4 | Forward PE - | Enterprise Value 2352814282 | Price to Sales(TTM) 5.01 |
Enterprise Value 2352814282 | Price to Sales(TTM) 5.01 | ||
Enterprise Value to Revenue 4.56 | Enterprise Value to EBITDA 403.44 | Shares Outstanding 43472900 | Shares Floating 33529273 |
Shares Outstanding 43472900 | Shares Floating 33529273 | ||
Percent Insiders 3.74 | Percent Institutions 93.08 |
Upturn AI SWOT
Kiniksa Pharmaceuticals Ltd
Company Overview
History and Background
Kiniksa Pharmaceuticals is a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients with significant unmet medical need. Founded in 2015, Kiniksa went public in 2018.
Core Business Areas
- Therapeutics Development: Focuses on developing therapies for autoinflammatory and autoimmune diseases with significant unmet needs.
- Commercialization: Involves the commercialization of Kiniksa's approved products, primarily focusing on ARCALYST (rilonacept).
Leadership and Structure
The leadership team consists of key executives including the CEO, CFO, and Chief Medical Officer. The organizational structure is typical of a biopharmaceutical company, with departments covering research and development, clinical trials, commercial operations, and corporate functions.
Top Products and Market Share
Key Offerings
- ARCALYST (rilonacept): ARCALYST is an interleukin-1u03b1 and interleukin-1u03b2 (IL-1u03b1 and IL-1u03b2) blocker indicated for recurrent pericarditis and cryopyrin-associated periodic syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS). Rilonacept faces competition from other anti-inflammatory agents like NSAIDs, colchicine, and corticosteroids for pericarditis, and other IL-1 inhibitors and targeted therapies for CAPS. Market share data for ARCALYST specifically is not readily available. Revenue can be found in the company's quarterly reports. Key competitors include Novartis(Gevokizumab in clinical trials) and SOBI (anakinra).
- Mavrilimumab (discontinued): Mavrilimumab was an investigational GM-CSF receptor alpha monoclonal antibody being developed for giant cell arteritis (GCA). Kiniksa discontinued the Mavrilimumab program in 2023 due to lack of efficacy demonstrated in Phase 3 study. Competitors included Actemra (tocilizumab) from Roche/Genentech.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high research and development costs, lengthy regulatory approval processes, and significant competition. There is a growing focus on precision medicine and targeted therapies.
Positioning
Kiniksa Pharmaceuticals is positioned as a developer of targeted therapies for autoinflammatory and autoimmune diseases. Its competitive advantage lies in its focus on specific pathways and patient populations with unmet needs.
Total Addressable Market (TAM)
The TAM for autoinflammatory and autoimmune diseases is substantial and growing, estimated to be in the billions of dollars annually. Kiniksa is positioned to capture a share of this market with its targeted therapies. Estimating the TAM for each individual condition Arcalyst treats would provide better details.
Upturn SWOT Analysis
Strengths
- Approved product (ARCALYST)
- Targeted therapy approach
- Experienced management team
- Focused on unmet medical needs
Weaknesses
- Reliance on a limited number of products (primarily ARCALYST)
- High research and development expenses
- Dependence on regulatory approvals
- Commercialization risks
Opportunities
- Expansion of ARCALYST indications
- Development of new therapies for autoinflammatory and autoimmune diseases
- Strategic partnerships and collaborations
- Geographic expansion
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles and delays
- Patent expirations
- Unfavorable clinical trial results
Competitors and Market Share
Key Competitors
- NVS
- SNY
Competitive Landscape
Kiniksa Pharmaceuticals faces strong competition from larger, more established pharmaceutical companies with greater resources. Its success depends on its ability to develop and commercialize innovative therapies and differentiate itself in the market.
Growth Trajectory and Initiatives
Historical Growth: Historical growth to be obtained from Kiniksa Pharmaceuticals Ltd's investor relations page or financial reporting sites (e.g., SEC filings).
Future Projections: Future projections to be obtained from analyst estimates, such as those provided by Yahoo Finance or other financial news sources.
Recent Initiatives: Recent strategic initiatives to be obtained from Kiniksa Pharmaceuticals Ltd's investor relations page or financial reporting sites (e.g., SEC filings). Discontinuation of mavrilimumab program.
Summary
Kiniksa Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for autoinflammatory and autoimmune diseases, primarily relying on ARCALYST. While its targeted approach and experienced management team provide strengths, its reliance on a limited number of products and high R&D costs pose challenges. The company needs to capitalize on opportunities like expanding Arcalyst's indications. Facing competition and regulatory hurdles, its success depends on innovation and strategic collaborations.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Industry publications
- Financial news sources
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market conditions and company performance can change rapidly.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Kiniksa Pharmaceuticals Ltd
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2018-05-24 | CEO & Chairman of the Board Mr. Sanj K. Patel | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 315 | Website https://www.kiniksa.com |
Full time employees 315 | Website https://www.kiniksa.com | ||
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, developing and commercializing novel therapies for diseases with unmet need and focuses on cardiovascular indications worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-387, an investigational, that is in Phase 2/3 clinical trial for human immunoglobulin G2 monoclonal antibody that binds human interleukin-1 receptor 1, inhibiting IL-1a, IL-1ß-mediated signaling for the treatment of advance recurrent pericarditis by providing the added convenience of monthly subcutaneous dosing with a liquid formulation. Its preclinical products include KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody. The company was formerly known as Kiniksa Pharmaceuticals, Ltd and changed its name tpKiniksa Pharmaceuticals International, plc in June 2024. The company was incorporated in 2015 and is based in London, the United Kingdom.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.